ClinicalTrials.gg
CompletedNCT03663101PMOD03Updated Jan 12, 2021Results posted

Dysport in Post-Surgical Neuralgia

A Phase 2 interventional study of Lidocaine and Botulinum toxin type A in Chronic Scar Pain, sponsored by Ipsen. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing botulinum toxin type A in Cicatrix — 1 open to participants now, 2 under way, none of them phase 3. botulinum toxin type A · Cicatrix.

Enrollment
10th of 12
16 · median 36
Started
2018
the only one that year
Phase 2
3 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
Ipsen

Among the 12 studies testing botulinum toxin type A in Cicatrix, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 3 in phase 2, and was the 7th registered.

Cicatrix

613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.

Browse Cicatrix studies →

Open to participants now

1 of the 12 studies testing botulinum toxin type A in Cicatrix is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing botulinum toxin type A in Cicatrix, or all of them as a file.
02

Study summary

The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous surgical site, and whether this condition could be suitable for the testing of similar new medicines. The study will compare three different doses of Dysport® to see if there is benefit and/or a best dose for treating persistent post-surgery scar pain.

03

Conditions studied

  • Chronic Scar Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged between 18 and 75 years inclusive at the time of giving .
  • Subjects suffering from an area of chronic pain post-abdominal or thoracic surgery, chronic abdominal or thoracic scar pain.
  • Longitudinal axis of the pain area of 10 cm long maximum (as mapped upon screening).
  • Subjects with moderate to severe pain, i.e. spontaneous NRS score of 4-8 which has been stable for the previous month before screening.
  • Stable use of analgesics (or any medication impacting pain perception) during the month before screening and expected to be stable for the study duration.
  • Under stable medication regimen for other medication, i.e. during the month before screening.
  • Time from surgery which caused the painful scar more than six months and less than ten years at screening.
  • No other distracting pain either chronic or acute.
  • Female subjects of must have a negative urine pregnancy test result and be willing to use reliable measures throughout study participation.
  • The subject's primary care physician has provided evidence which can be used to confirm that within the last 12 months of dosing that there is nothing in their medical history that would preclude their enrolment into a clinical study.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Botulinum neurotoxin (BTX) (any serotype) during the past six months before screening.
  • History of to any of the components of the Dysport formulation (which includes human serum albumin and lactose) or allergy to cow's milk protein.
  • Known hypersensitivity to lidocaine or other anaesthetics of the amide type, known hypersensitivity to hydroxybenzoates, complete heart block, hypovolaemia.
  • Any medical condition that may put the subject at risk with exposure to BTX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.
  • Opioid analgesic use at a Morphine Equivalent Dosage (MED) of >75mg per day.
  • Neuroma in the scar pain area, diagnosed per ultrasound.
  • Use of agents that could interfere with neuromuscular transmission, including calcium channel blockers, penicillamine, aminoglycosides, lincosamides, polymixins, magnesium sulphate, anticholinesterases, succinylcholine and quinidine.
  • Need of any prohibited medication.
  • Any abnormal laboratory value, physical examination, vital signs, or (ECG) that, in the opinion of the investigator, is and that would compromise the safety of the subject in the study.
  • Positive for antigen or virus ribonucleic acid, positive results for , or who receives diagnosis for acquired immunodeficiency syndrome.
  • Positive urine screen for drugs of abuse (except for cotinine and unless explained by the investigator for therapeutic use of medication) or any history of drug or alcohol abuse, misuse, physical or psychological dependence, mood changes, sleep disturbance and functional capacity which have an impact on pain perception.
  • Significant neurological or psychiatric disorders including mental instability (unrelated to the pain) that could interfere with pain assessments; other pre-existing pain syndromes, acute or chronic, that might impair the assessment of the scar pain.
  • Any medical history of significance and/or inadequately controlled such as cardiovascular (e.g. uncontrolled high blood pressure, high risk of cardiovascular events, severe heart failure), pulmonary (e.g. uncontrolled asthma or emphysema), haematologic, (e.g. coagulopathy/bleeding disorders), neurological (e.g. swallowing problems, blurred or double vision, trouble saying words clearly (dysarthria), hoarseness or change or loss of voice (dysphonia)), liver disease (e.g. severe hepatic impairment), kidney disease (e.g. impaired renal function in subjects taking diuretics, angiotensin converting enzyme (ACE)-inhibitors, or angiotensin II antagonists), endocrine, immunologic, dermatologic painful conditions or any other conditions that may compromise in the opinion of the investigator the ability of the subject to participate in the study.
  • Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days before screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Pre-Randomization, Run-In period (part A)

    Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).

    Drug: Lidocaine · Drug: Placebo

  • Experimental
    Dysport dose 1 (part B)

    Dysport dose 1 as a single-dose, intradermal injection.

    Biological: Botulinum toxin type A

  • Experimental
    Dysport dose 2 (part B)

    Dysport dose 2 as a single-dose, intradermal injection.

    Biological: Botulinum toxin type A

  • Experimental
    Dysport dose 3 (part B)

    Dysport dose 3 as a single-dose, intradermal injection.

    Biological: Botulinum toxin type A

  • Placebo comparator
    Placebo (saline solution) (part B)

    Placebo single-dose, intradermal injection.

    Drug: Placebo

Interventions

  • 0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).

  • 0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).

    Also known as: AbobotulinumtoxinA (Dysport®)

  • DrugPlacebo

    Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).

    Also known as: Saline solution

  • DrugPlacebo

    Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).

06

What researchers measure

Primary outcomes

  1. Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score

    The time to onset of effect was defined as the time to a decrease from baseline of two points or greater in the spontaneous NRS score. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Only descriptive statistical analysis was performed for this outcome measure.

    Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.

  2. Peak Effect in the Spontaneous NRS Score

    The peak effect was defined as the maximal decrease from baseline in the spontaneous NRS score over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.

    Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.

  3. Time to Peak Effect in the Spontaneous NRS Score

    The time to peak effect was defined as the time to reach the peak effect over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."

    Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.

  4. Duration of Effect in the Spontaneous NRS Score

    The duration of effect was defined as the duration between time to onset and last timepoint for which decrease from baseline in the spontaneous NRS score was two points or greater. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."

    Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.

Secondary outcomes

  1. Change From Baseline in the Spontaneous NRS Score Throughout the Study

    Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.

    Time frame: Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.

  2. Change From Baseline in the Stimulus-Evoked NRS Score on the Painful Area at Weeks 6 and 12

    For stimulus-evoked NRS score during Quantitative Sensory Testing, participants were submitted to stimuli of various nature (light touch, pressure and temperature) applied to the painful area. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Static mechanical allodynia is the response to light sustained normally innocuous pressure against the skin. Dynamic mechanical allodynia is the response to a normally innocuous light moving mechanical stimulus on the skin. Temporal summation is a condition, which demonstrates an increased perception of pain to repetitive painful stimuli.

    Time frame: Part B: Baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) and Weeks 6 and 12

07

Results

Posted Dec 4, 2020
Limitations and caveats
Recruitment was closed prematurely by 30 June 2019 due to slow enrolment (16 participants randomized instead of 24 initially planned), which meant Sponsor did not believe it was feasible to continue study in an acceptable timeframe. The decision was not related to any safety/tolerability concern with Dysport.

Participant flow

This Phase II proof-of-concept study was conducted at single investigational site in the United Kingdom between 30 October 2018 and 08 November 2019. The study consisted of two sequential parts: Part A (Pre-randomisation run-in period) and Part B (Randomised double-blind period). Part A was considered as an extended screening period.

Participant flow — Overall Study
MilestonePlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Started4354
Completed4354
Not completed0000

Outcome measures

PrimaryTime to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score

The time to onset of effect was defined as the time to a decrease from baseline of two points or greater in the spontaneous NRS score. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Only descriptive statistical analysis was performed for this outcome measure.

Time frame:
Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Reported as:
Mean · days
Time to Onset of Effect in the Spontaneous Numerical Rating Scale (NRS) Score
daysPlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Worst NRS score4.41 ± 4.9215.11 ± 25.1729.45 ± 39.820.65 ± 0.32
Average NRS score6.75 ± 2.7431.63 ± 53.784.60 ± 6.550.90 ± 0.03
PrimaryPeak Effect in the Spontaneous NRS Score

The peak effect was defined as the maximal decrease from baseline in the spontaneous NRS score over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.

Time frame:
Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Reported as:
Mean · score on a scale
Peak Effect in the Spontaneous NRS Score
score on a scalePlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Worst NRS score-2.36 ± 1.58-4.73 ± 0.55-3.54 ± 2.15-2.82 ± 2.91
Average NRS score-2.52 ± 0.91-3.53 ± 0.45-3.72 ± 1.57-2.12 ± 2.37
PrimaryTime to Peak Effect in the Spontaneous NRS Score

The time to peak effect was defined as the time to reach the peak effect over a 12-hour period. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."

Time frame:
Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Reported as:
Mean · days
Time to Peak Effect in the Spontaneous NRS Score
daysPlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Worst NRS score10.63 ± 10.1833.46 ± 51.4141.94 ± 35.723.11 ± 1.56
Average NRS score12.51 ± 7.2633.13 ± 52.5111.04 ± 11.5826.49 ± 49.89
PrimaryDuration of Effect in the Spontaneous NRS Score

The duration of effect was defined as the duration between time to onset and last timepoint for which decrease from baseline in the spontaneous NRS score was two points or greater. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours."

Time frame:
Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Reported as:
Mean · days
Duration of Effect in the Spontaneous NRS Score
daysPlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Worst NRS score86.04 ± 25.5286.68 ± 23.8966.80 ± 44.28110.52 ± 0.74
Average NRS score53.53 ± 51.4465.17 ± 58.21102.75 ± 18.36110.02 ± 1.45
SecondaryChange From Baseline in the Spontaneous NRS Score Throughout the Study

Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Participants were provided with an Actiwatch® during an Actiwatch® training visit to record their spontaneous NRS scores at home. The Actiwatch® alerted the participants twice a day to record their average and maximal NRS scores over the preceding 12 hours. The questions were asked of the participants by the Actiwatch®: "Please rate your pain by selecting the one number that best describes your pain on average during the last 12 hours." and "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 12 hours." Greater reductions in change from baseline correspond to greater pain relief.

Time frame:
Part B: From baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) up to end of study (Week 16) or early discontinuation.
Reported as:
Mean · score on a scale
Change From Baseline in the Spontaneous NRS Score Throughout the Study
score on a scalePlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Daily worst NRS score: Baseline5.1 ± 1.05.1 ± 1.05.3 ± 1.65.8 ± 0.9
Daily worst NRS score: Week 2-0.6 ± 0.9-2.1 ± 2.1-1.4 ± 3.5-1.1 ± 2.7
Daily worst NRS score: Week 4-1.6 ± 1.8-2.1 ± 1.8-1.4 ± 4.2-1.6 ± 2.7
Daily worst NRS score: Week 6-1.1 ± 0.7-0.1 ± 1.0-1.7 ± 2.9-1.6 ± 2.6
Daily worst NRS score: Week 12-0.5 ± 1.4-1.4 ± 0.6-0.7 ± 1.1-0.8 ± 3.3
Daily worst NRS score: Week 16-0.0 ± 2.0-1.4 ± 1.1-1.3 ± 3.1-0.3 ± 1.7
Daily average NRS score: Baseline4.5 ± 1.13.9 ± 1.04.7 ± 1.24.9 ± 1.2
Daily average NRS score: Week 2-0.9 ± 1.0-2.0 ± 1.8-2.1 ± 2.8-1.7 ± 2.5
Daily average NRS score: Week 4-1.6 ± 1.9-1.9 ± 1.3-2.1 ± 3.2-1.4 ± 2.0
Daily average NRS score: Week 6-1.0 ± 0.9-0.4 ± 2.0-2.0 ± 2.6-1.4 ± 2.0
Daily average NRS score: Week 12-0.5 ± 1.6-1.5 ± 0.6-1.2 ± 1.9-0.6 ± 2.5
Daily average NRS score: Week 16-0.6 ± 1.5-0.9 ± 0.8-1.6 ± 2.3-0.4 ± 1.5
SecondaryChange From Baseline in the Stimulus-Evoked NRS Score on the Painful Area at Weeks 6 and 12

For stimulus-evoked NRS score during Quantitative Sensory Testing, participants were submitted to stimuli of various nature (light touch, pressure and temperature) applied to the painful area. Pain intensity was scored using an 11-point NRS score ranging from 0 to 10, where 0= no pain and 10= worst possible pain. Static mechanical allodynia is the response to light sustained normally innocuous pressure against the skin. Dynamic mechanical allodynia is the response to a normally innocuous light moving mechanical stimulus on the skin. Temporal summation is a condition, which demonstrates an increased perception of pain to repetitive painful stimuli.

Time frame:
Part B: Baseline (defined as mean of all predose data from Day -7 and including predose on Day 1) and Weeks 6 and 12
Reported as:
Mean · score on a scale
Change From Baseline in the Stimulus-Evoked NRS Score on the Painful Area at Weeks 6 and 12
score on a scalePlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Static mechanical allodynia: Baseline1.3 ± 1.53.0 ± 3.64.2 ± 1.14.5 ± 3.1
Static mechanical allodynia: Week 61.0 ± 1.2-1.7 ± 4.0-2.6 ± 1.8-1.0 ± 5.5
Static mechanical allodynia: Week 120.8 ± 1.0-0.3 ± 5.7-2.0 ± 1.4-0.8 ± 5.1
Dynamic mechanical allodynia: Baseline1.3 ± 1.02.3 ± 3.22.4 ± 1.75.3 ± 1.0
Dynamic mechanical allodynia: Week 6-0.5 ± 1.0-1.7 ± 2.1-2.0 ± 1.9-2.5 ± 2.6
Dynamic mechanical allodynia: Week 12-0.3 ± 2.1-1.3 ± 1.5-0.2 ± 1.5-2.0 ± 2.7
Temporal summation: Baseline1.5 ± 1.30.3 ± 1.53.6 ± 3.01.8 ± 2.1
Temporal summation: Week 61.8 ± 2.10.3 ± 0.61.8 ± 1.12.8 ± 1.7
Temporal summation: Week 122.0 ± 0.80.3 ± 3.11.4 ± 1.12.8 ± 1.7

Adverse events

Collected over Treatment-emergent adverse events were collected from the start of study drug administration (Day 1) in Part B up to end of study visit or early discontinuation, approximately 16 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Dysport 2.5 U/Injection Site0/3 (0%)1/3 (33.3%)3/3 (100%)
Dysport 10 U/Injection Site0/5 (0%)0/5 (0%)4/5 (80%)
Dysport 20 U/Injection Site0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
Pancreatogenous diabetesMetabolism and nutrition disorders0/41/30/50/4
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection Site
HeadacheNervous system disorders0/40/32/53/4
NasopharyngitisInfections and infestations2/40/32/50/4
DizzinessNervous system disorders0/41/31/51/4
ParaesthesiaNervous system disorders0/41/30/50/4
DyspnoeaRespiratory, thoracic and mediastinal disorders0/41/31/50/4
Nasal congestionRespiratory, thoracic and mediastinal disorders0/41/30/50/4
DiarrhoeaGastrointestinal disorders1/41/30/50/4
VomitingGastrointestinal disorders0/41/30/51/4
Abdominal painGastrointestinal disorders0/41/30/50/4
Gastric mucosa erythemaGastrointestinal disorders0/41/30/50/4

Baseline characteristics

Randomised population included all participants randomised in the double-blind period (Part B).

Age, Continuous
Age, Continuous(years)PlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection SiteTotal
Mean56.5 ± 10.749.7 ± 6.046.0 ± 11.348.8 ± 16.750.0 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection SiteTotal
Female333211
Male10225
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDysport 2.5 U/Injection SiteDysport 10 U/Injection SiteDysport 20 U/Injection SiteTotal
American Indian or Alaska Native00000
Asian00314
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White432312
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • St Pancras Clinical Research
    London, WC1X8QD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2019, 12 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 24 phase 2 interventional studies under Cicatrix, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 61. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Sep 10, 2018
StartActual
Oct 30, 2018
Primary completionActual
Nov 8, 2019
CompletionActual
Nov 8, 2019
Results first posted
Dec 4, 2020
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03663101
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 10, 2018
Start date
Oct 30, 2018
Primary completion
Nov 8, 2019
Completion
Nov 8, 2019
Results posted
Dec 4, 2020
Last update
Jan 12, 2021

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Botulinum toxin type A

Start the discussion